Home » Stocks » HTBX

Heat Biologics, Inc. (HTBX)

Stock Price: $6.25 USD -0.29 (-4.43%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $6.44 +0.19 (3.04%) May 7, 7:41 PM
Market Cap 166.95M
Revenue (ttm) 2.58M
Net Income (ttm) -27.29M
Shares Out 24.20M
EPS (ttm) -1.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $6.25
Previous Close $6.54
Change ($) -0.29
Change (%) -4.43%
Day's Open 6.47
Day's Range 6.21 - 6.69
Day's Volume 400,440
52-Week Range 3.71 - 30.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

InspireMD has vastly reduced the number of its shares trading ahead of a likely move to a Nasdaq listed. Conversion of NSPR stock warrants and preferred shares will be more difficult now.

Other stocks mentioned: NSPR
1 week ago - InvestorPlace

DURHAM, NC / ACCESSWIRE / April 12, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, in...

3 weeks ago - Accesswire

DURHAM, NC / ACCESSWIRE / March 25, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, in...

1 month ago - Accesswire

DURHAM, NC / ACCESSWIRE / March 8, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, inc...

2 months ago - Accesswire

Heat Biologics (HTBX) stock is heating up on Wednesday following new coverage from Cantor Fitzgerald analyst Kristen Kluska. The post HTBX Stock: Why Shares of Heat Biologics Are Blazing Higher Today ap...

2 months ago - InvestorPlace

Heat Biologics said Tuesday adding its experimental drug to Bristol Myers Squibb's Opdivo helped more lung-cancer patients survive. In response, HTBX stock catapulted.

2 months ago - Investors Business Daily

Heat Biologics (HTBX) stock is heating up on Tuesday after revealing interim data from a Phase 2 trial of its lung cancer treatment. The post Heat Biologics News: Why HTBX Stock Is Going Gangbusters Tod...

2 months ago - InvestorPlace

Heat Biologics Inc (NASDAQ: HTBX) soars in premarket on the heels of encouraging interim data from the Phase 2 trial evaluating HS-110, in combination with Bristol-Myers Squibb's (NYSE: BMY) Opdivo (niv...

2 months ago - Benzinga

Heat Biologics: Investors Would Be Wise To Hold Off Until 2H 2021 Clinical Trial Interim Results

3 months ago - Seeking Alpha

DURHAM, NC / ACCESSWIRE / January 19, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...

3 months ago - Accesswire

DURHAM, NC / ACCESSWIRE / January 11, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...

3 months ago - Accesswire

DURHAM, NC / ACCESSWIRE / January 8, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune ...

3 months ago - Accesswire

Esperion Therapeutics (NASDAQ: ESPR) shares are trading higher on Wednesday after the company announced Swiss Approval for the first-in-class cholesterol-lowering treatment NILEMDO and its Combination w...

Other stocks mentioned: ESPR, BLRX
4 months ago - Benzinga

Heat Biologics (HTBX) has announced details for a reverse stock split in order to keep shares of HTBX stock trading on the Nasdaq. The post Heat Biologics Reverse Stock Split: 10 Things for HTBX Stock I...

4 months ago - InvestorPlace

Heat Biologics boosts patents portfolio with gp96 combination award. Teleflex announces acquisition of hemostatic company Z-Medica.

6 months ago - Seeking Alpha

Heat Biologics (HTBX) is in the news Thursday as HTBX stock takes a wild ride following an increasing focus on coronavirus stocks. The post Heat Biologics News: Why HTBX Stock Is On the Move Today appea...

7 months ago - InvestorPlace

COVID-19 vaccine stocks have gotten slammed this month.

Other stocks mentioned: AZN, BNTX, GSK, INO, JNJ, MRNA, NVAX ...
8 months ago - The Motley Fool

A pre-print is sending the biotech's shares higher today.

8 months ago - The Motley Fool

Reports of an early approval for AstraZeneca's COVID-19 vaccine are sending these three stocks lower today.

Other stocks mentioned: INO, NVAX
8 months ago - The Motley Fool

Encouraging early results for the biotech's coronavirus vaccine have investors excited.

8 months ago - The Motley Fool

Russia's surprise vaccine announcement isn't sitting well with shareholders of Dynavax, Heat Biologics, or Inovio Pharmaceuticals.

Other stocks mentioned: DVAX, INO
8 months ago - The Motley Fool

Heat Biologics and Vaxart could have a lot more room to run.

Other stocks mentioned: VXRT
9 months ago - The Motley Fool

The biotech's COVID-19 vaccine candidate hit the mark in a preclinical study.

9 months ago - The Motley Fool

Heat Biologics Inc (NASDAQ: HTBX) shares are trading higher on Monday after the company announced the first patient has been treated in its first-in-human clinical trial of PTX-35.

10 months ago - Benzinga

The market is powering through its third consecutive day of massive gains. Whether the market is too optimistic has been on the minds of many, considering how unstable the economy has been this year.

Other stocks mentioned: BAND, COF, EYPT, GHSI
11 months ago - Forbes

As tensions continue to rise both domestically and internationally, taking a short position isn't a bad idea. Our deep learning algorithms have identified these 5 companies as the top stocks to short to...

Other stocks mentioned: BBI, DGLY, EYPT, MNKD
11 months ago - Forbes

About HTBX

Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with a... [Read more...]

Industry
Biotechnology
IPO Date
Jul 24, 2013
CEO
Jeffrey Wolf
Employees
39
Stock Exchange
NASDAQ
Ticker Symbol
HTBX
Full Company Profile

Financial Performance

In 2020, Heat Biologics's revenue was $2.95 million, a decrease of -3.32% compared to the previous year's $3.05 million. Losses were -$26.05 million, 30.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Heat Biologics stock is "Strong Buy." The 12-month stock price forecast is 26.00, which is an increase of 316.00% from the latest price.

Price Target
$26.00
(316.00% upside)
Analyst Consensus: Strong Buy